HOME >> BIOLOGY >> NEWS
New antimalarial combination confirms its potential use in treating drug-resistant malaria

Yaound, Cameroon, 15th November 2005 Clinical results demonstrating the potential benefits of treating Plasmodium falciparum malaria with a new artemisinin-based combination therapy (ACT), chlorproguanil hydrochloride-dapsone-artesunate (CDA)1, were announced today at the 4th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Cameroon. CDA is being developed to meet the urgent need for new malaria treatments for Africa where drug resistance is contributing to an escalating health crisis. Dr. Arata Kochi, Director of the WHO Roll Back Malaria (RBM) Department stated, "The effort to develop CDA responds to RBM's call for fixed-dose artemisinin containing combinations."

The phase II trial of CDA, involving adults and children with P. falciparum malaria, was designed to determine the optimum dose of artesunate in combination with LapdapTM (chlorproguanil/dapsone). Treatment with CDA, at three doses of artesunate (1, 2 and 4mg/kg) in adults and at two doses (2 and 4mg/kg) in children, led to faster time to reduce parasite levels in the blood by 90 percent when compared to treatment with Lapdap alone.1 Reductions in parasite viability and potential parasite reproductive ability in patients were also greater in those treated with CDA than Lapdap alone. All treatment doses of CDA were generally well tolerated, and the nature and incidence of adverse events were similar across treatment groups.1

"These results suggest that CDA could become a major weapon in the fight against drug-resistant malaria. Moving into phase III trials marks a key step in the development of this promising antimalarial," commented Dr. Chris Hentschel, CEO of MMV.

Phase III trials for CDA are planned across sub-Saharan Africa and will further study the safety and efficacy of treating P. falciparum malaria with CDA. One study will compare CDA against the only fixed-dose ACT currently available for the treatment of P. falciparum, artemether/lumefantrine, over a
'"/>


15-Nov-2005


Page: 1 2

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Research milestone brings goal closer of cheap antimalarial drug for developing world
3. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World
4. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
5. New study suggests promising drug combinations for sleeping sickness
6. Recombination protein dynamics observed with single monomer resolution
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New combination treatment induces regression of prostate cancer
9. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
10. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
11. Pesticide combinations imperil frogs, probably contribute to amphibian decline

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... announced that an extensive third-party assessment of the company’s security practices has been ... against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing ...
(Date:8/23/2020)... , ... August 21, 2020 , ... ... Corporation has been published and is now available on the company’s global ... diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. , ...
(Date:8/12/2020)... , ... August 11, 2020 , ... ... based in Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI ... Both Roche and J&J have annual Research and Development spending in excess ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine ... global leader in FDA compliance consulting has been named on its annual Inc. ... list represents a unique look at the most successful companies within the American ...
(Date:7/31/2020)... STATION, Texas (PRWEB) , ... July 29, 2020 ... ... cleanroom solutions today announced the launch of its new tagline, “BUILDING FOR LIFE.” ... the biopharmaceutical industry and around the globe, requiring fast track capacity to provide ...
(Date:7/31/2020)... ... , ... The SDX® Respiratory Gating System , trusted ... its 20th anniversary of worldwide use. Introduced in the US over the past ... of Pennsylvania, University of Michigan, University of Maryland, University of California San Francisco—and ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
Breaking Biology Technology:
Cached News: